Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY20.70 CNY
Change Today +1.25 / 6.43%
Volume 22.4M
002693 On Other Exchanges
Symbol
Exchange
Shenzhen
As of 3:00 AM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by HAINAN SHUANGCHENG PHARMAC-A (002693) in the last 6 months

Announced 05/7/15
74.9% Stake In Lyomark Pharma GmbH And 74.9% Stake In Bendalis GmbH
Merger/Acquisition

Hainan Shuangcheng Pharmaceutical Co., Ltd. (SZSE:002693) signed a letter of intent to acquire a 74.9% stake in Lyomark Pharma GmbH and 74.9% stake in Bendalis GmbH from Lothar Böning and Helmut Wolf on May 7, 2015. The deal value is in the range of CNY 70 million to CNY 200 million. Lyomark has total assets of CNY 44.79 million (€6.6 million) by the end of 2014. Bendalis had total assets of CNY 19 million (€2.8 million) by the end of 2014. The conversion was done through ...
Read More


002693's price was unchanged after the transaction was announced on 05/7/15.
Investor / Buyer
Hainan Shuangcheng Pharmaceutical Co., Ltd.
 
Announced 02/3/15
505.00M for Hangzhou Ausia Biological Technology Company, Ltd
Merger/Acquisition

Hainan Shuangcheng Pharmaceutical Co., Ltd. (SZSE:002693) agreed to acquire a 46% stake in Hangzhou Aoya Biotechnology Co Ltd. from Zhejiang Juke Industrial Co., Ltd. for approximately CNY 510 million on January 31, 2015. In a related deal, Hainan Shuangcheng Pharmaceutical Co., Ltd. (SZSE:002693) agreed to acquire Hangzhou Aopeng Investment for approximately CNY 960 million on February 3, 2015. On February 2, 2015, Hainan Shuangcheng paid a CNY 300 million deposit; ...
Read More


002693's price was unchanged after the transaction was announced on 02/3/15.
Investor / Buyer
Hainan Shuangcheng Pharmaceutical Co., Ltd.
Creditor / Lender
Zhejiang Juke Industrial Co., Ltd.
 
Announced 02/3/15
962.00M for Hangzhou Aopeng Investment Management Co., Ltd.
Merger/Acquisition

Hainan Shuangcheng Pharmaceutical Co., Ltd. (SZSE:002693) entered into framework agreement to acquire Hangzhou Aopeng Investment Management Co., Ltd. from Huang Shaofeng and Zhou Yulan for approximately CNY 960 million on January 31, 2015. Hainan Shuangcheng Pharmaceutical Co., Ltd. will acquire 81% stake from Huang Shaofeng for CNY 779.14 million and 19% stake from Zhou Yulan for CNY 182.76 million. Within 10 days after the private placement proceeds are in place, Hainan ...
Read More


002693's price was unchanged after the transaction was announced on 02/3/15.
Investor / Buyer
Hainan Shuangcheng Pharmaceutical Co., Ltd.
 
Announced 01/31/15
900.00M for Hainan Shuangcheng Pharmaceutical Co., Ltd.
Private Placement

Hainan Shuangcheng Pharmaceutical Co., Ltd. (SZSE:002693) announced a private placement of up to 74,318,744 A shares at no less than CNY 12.11 per share for gross proceeds of up to CNY 900,000,000 on January 31, 2015. The transaction will include participation from 10 designated investors. The transaction has been approved in its 18th meeting of the 2nd directorate and 13th meeting of the 2nd supervisory board and is still subject to shareholders' approval and China ...
Read More


002693's price was unchanged after the transaction was announced on 01/31/15.
 
Announced 01/29/15
19.00M for Hainan Weile Pharmaceutical Co., Ltd.
Private Placement

Hainan Weile Pharmaceutical Co., Ltd. announced that it will receive CNY 19,000,000 in an equity round of funding from existing investor Hainan Shuangcheng Pharmaceutical Co., Ltd. on January 29, 2015. The company announced that the transaction has been approved by the 17th meeting of the 2nd directorate of the investor. Following the transaction, the registered capital of the company will increase from CNY 1,000,000 to CNY 20,000,000.


002693's price was unchanged after the transaction was announced on 01/29/15.
Investor / Buyer
Hainan Shuangcheng Pharmaceutical Co., Ltd.
 
Announced 12/23/14
96.00M for Ningbo Shuangcheng Pharmaceuticals Co., Ltd.
Private Placement

Ningbo Shuangcheng Pharmaceuticals Co., Ltd. announced that it will receive an equity round of funding from existing investor, Hainan Shuangcheng Pharmaceutical Co., Ltd. on December 23, 2014. The transaction was approved at the 11th session of the 2nd supervisory board meeting of the investor. On closing, the investor will continue to hold its 100% stake in the company. On January 13, 2015, the company announced that it will receive CNY 96,000,000 in funding. The transaction ...
Read More


002693's price was unchanged after the transaction was announced on 12/23/14.
Investor / Buyer
Hainan Shuangcheng Pharmaceutical Co., Ltd.
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
002693:CH CNY20.70 CNY +1.25

002693 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002693.
View Industry Companies
 

Industry Analysis

002693

Industry Average

Valuation 002693 Industry Range
Price/Earnings 100.0x
Price/Sales 57.3x
Price/Book 10.9x
Price/Cash Flow 136.6x
TEV/Sales 44.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HAINAN SHUANGCHENG PHARMAC-A, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.